- Sign-on
Letter with list of signatories
- November 22, 2005: Grover Norquist letter to DEA
- Organizations Writing to DEA Supporting Prof. Craker
- Case For A Sign-On Letter to DEA Administrator
Karen Tandy supporting Proposed UMASS Amherst Marijuana Production
Facility
- Background on the University of Massachusetts Amherst
Marijuana Production Facility Project
- Statement Of Frederic M. Scherer, professor emeritus
at the John F. Kennedy School of Government, Harvard University.
- August 27, 2005, New York Times Op-Ed, "Marijuana
Pipe Dreams," by John Tierney.
- MAPS/Craker/DEA hearing transcripts
|
Click
for a copy of the final letter sent December 6, 2005, PDF Format
DEA Administrator Karen P. Tandy
Drug Enforcement Administration
Mailstop: AXS
2401 Jefferson Davis Highway
Alexandria, VA 22301
Dear Administrator Tandy,
We are writing to express our strong support for the application
from Professor Craker, of the University of Massachusetts-Amherst,
for licensing as a bulk manufacturer of marijuana for distribution
exclusively to federally-approved researchers. We believe the DEA
licensing of Prof. Craker's privately-funded facility would be in
the public interest.
At present, the National Institute on Drug Abuse (NIDA) has an
unjustifiable monopoly on the production of marijuana for legitimate
medical and research purposes in the United States, grown under
contract to NIDA at the University of Mississippi. Federal law clearly
requires adequate competition in the manufacture of Schedule I and
II substances. (See 21 U.S.C. § 823(a)(1); see also 21 C.F.R.
§ 1301.33(b).) The licensing of Prof. Craker's facility would
provide privately-funded sponsors of FDA-approved research the necessary
opportunity to conduct studies with a strain of marijuana of their
own choosing, with immediate access to the strain for all FDA-approved
studies and for possible prescription use. None of this is the case
under NIDA's monopoly. Until an alternative source of supply is
available, important privately-funded research into the therapeutic
effects of marijuana for patients undergoing chemotherapy or suffering
from AIDS, glaucoma, multiple sclerosis, or other diseases will
not be initiated.
The University of Massachusetts-Amherst is one of the nation's
distinguished research universities, and it is highly qualified
to manufacture marijuana for legitimate medical and research purposes
with effective controls against diversion. NIDA's monopoly makes
very little sense given that the DEA has licensed privately-funded
manufacturers of virtually all other Schedule I drugs, including
LSD, MDMA (Ecstasy), and psilocybin.
As one of your predecessors, DEA Administrator Robert Bonner, stated,
"Those who insist that marijuana has medical uses would serve
society better by promoting or sponsoring more legitimate scientific
research, rather than throwing their time, money and rhetoric into
lobbying public relations campaigns and perennial litigation."
We urge you to grant Prof. Craker's application for registration
as a bulk manufacturer so that such legitimate and privately-funded
scientific research can be conducted.
Respectfully,
|
|
PDF
Version | MS WORD Version
November 22, 2005
DEA Administrator Karen P. Tandy
Drug Enforcement Administration
Mailstop: AXS
2401 Jefferson Davis Highway
Alexandria, VA 22301
Dear Administrator Tandy:
I am writing today to urge the DEA to license a privately-funded
medical marijuana production facility, thus ending the government
monopoly on the supply of marijuana legal for FDA and DEA-approved
research. This would allow more controlled medical research using
cannabis plants. When in a controlled laboratory facility,
any agricultural product should be fair game for research and experimentation.
Over four years ago, Prof. Lyle Craker, University of Massachusetts-Amherst,
sought permission from DEA to grow cannabis for privately-funded
medicinal research. As a controlled substance, the DEA has discretion
to grant permission to grow the cannabis plant. The licensing of
this facility would provide privately-funded sponsors of FDA-approved
research the necessary opportunity to conduct studies with a strain
of cannabis of their own choosing, with immediate access to that
strain for all FDA-approved studies and for possible prescription
use.
Scientific research on agricultural products should
not be influenced by politics. If the test subject
in question were dandelions, there would be no controversy here.
The fact that some choose to abuse the cannabis plant illegally
is immaterial. The use of controlled substances for legitimate research
purposes is well-established, and has yielded a number of miracle
medicines widely available to patients and doctors. This case should
be no different. It’s in the public interest to end the government
monopoly on marijuana legal for research.
Sincerely,
Grover Norquist
President, Americans for Tax Reform
www.atr.org |
|
American Medical Students Association
California
Medical Association Lymphoma
Foundation of America New
Mexico Nurses Association
North Carolina Nurses Association Texas
Medical Association United
Methodist Church (UMC), with more than eight million members
Wisconsin Nurses Association |
|
CASE FOR A SIGN-ON LETTER
TO DEA ADMINISTRATOR KAREN TANDY SUPPORTING PROPOSED UMASS-AMHERST
MARIJUANA PRODUCTION FACILITY
GENERAL POLICY ISSUE: Should the controversy
over the medical use of marijuana be resolved through FDA-approved
scientific research or through legal and political struggles? Should
the federal government facilitate or obstruct scientific research?
SPECIFIC POLICY ISSUE: Is it in the public interest
for DEA to license Prof. Lyle Craker, Director, Medicinal Plant
Program, Dept. of Plant, Soil and Insect Sciences, University of
Massachusetts Amherst, to establish a privately-funded facility
to produce marijuana exclusively for federally-approved and privately-funded
research, or should the federal government, through the National
Institute on Drug Abuse (NIDA), retain its unique monopoly on the
supply of marijuana that can legally be used in research?
CONTEXT: On June 6, 2005, the US Supreme Court
ruled, in Gonzales v. Raich, that the federal government can arrest
patients who use marijuana with their doctor’s recommendation
even if it is legal under state law. On June 29, 2005, the US House
of Representatives defeated the Hinchey Amendment, 161-264, which
would have prohibited the use of federal funds for the prosecution
of medical marijuana users in states that have passed laws allowing
medical marijuana programs.
Currently, the only process that could result in marijuana becoming
legal as a medicine under federal law is for privately-funded sponsors
to conduct scientific research with the aim of obtaining FDA approval
for its use as a prescription medicine. Unfortunately, NIDA’s
monopoly on the supply of legal marijuana is a fundamental obstruction
to privately-funded research, none of which is currently taking
place despite strong interest. The DEA wants to have it both ways,
denying that marijuana is a medicine because the FDA has not approved
it while simultaneously blocking research by refusing to allow the
University of Massachusetts Amherst to manufacture marijuana for
medical research.
NIDA’s monopoly is against the public interest and may be
contrary to federal law, which clearly requires adequate competition
in the manufacture of Schedule I and II substances for research
purposes. [See 21 U.S.C. § 823(a)(1); see also 21 C.F.R. §
1301.33(b).] Researchers have unobstructed access to other Schedule
I and II drugs and marijuana should be no exception. Professor Craker
is suing the DEA in a DEA Administrative Law Judge hearing, but
the DEA can approve the project at any time.
MONOPOLY PROBLEMS: NIDA’s monopoly results
in arbitrary and lengthy delays or refusals in providing research
material. Chemic Labs, a DEA-licensed analytical lab, was made to
wait over two years for a reply to its request to purchase 10 grams
for research into vaporizers, a non-smoking delivery system which
the Institute of Medicine report recommended be developed. On July
27, 2005, NIDA refused to sell Chemic Labs the 10 grams, preventing
the study from taking place. NIDA has also refused to provide marijuana
to two FDA-approved protocols (Dr. Abrams, UC San Francisco, marijuana
for AIDS wasting syndrome-IND #43-542; Dr. Russo, U. Montana, marijuana
for migraines –IND #58,177). NIDA’s monopoly prevents
sponsors from conducting research with the strain of marijuana they
believe has the most potential. Furthermore, NIDA can legally provide
marijuana for research but is not authorized to provide it for prescription
use, should FDA approve such use. As a result, the strain of marijuana
NIDA provides for research might not even be available for prescription
use, an unacceptable uncertainty to sponsors.
RECOMMENDATION: The FDA cannot consider approving
marijuana for medical use until the federal government’s unique
monopoly on the production of marijuana for medical research is
broken. Members of Congress should sign onto a letter to DEA Administrator
Karen Tandy urging the DEA to approve Professor Craker’s application
in order to facilitate medical marijuana research.
|
|
The University of Massachusetts-Amherst
(Dr.Lyle Craker, Director, Medicinal Plant Program, UMass Amherst
Department of Plant and Soil Sciences) in association with Multidisciplinary
Association for Psychedelic Studies (MAPS) is in the midst of the
process of seeking DEA permission to establish a medical marijuana
production facility to grow high-potency marijuana for FDA-approved
research.
At present, the National Institute on Drug Abuse (NIDA) has a monopoly
on the supply of marijuana that can be used in research, seriously
hindering medical marijuana research. NIDA provides inferior, low-potency
marijuana to researchers whose protocols it approves and denies
marijuana even to FDA-approved protocols it doesn't approve, preventing
those studies from taking place.
No privately-funded sponsor (such as MAPS or alternatively a for-profit
pharmaceutical company) will invest significant sums in a realistic
drug development research program aimed at obtaining FDA-approval
for the prescription use of marijuana without first obtaining its
own independent source of supply of a drug whose quality, price
and availability it determines. There have been no US-based privately-funded
marijuana production facilities since 1942, when marijuana was removed
from the US Pharmacopoeia and its medical use was prohibited.
Dr. Lyle Craker originally submitted the application for a license
to DEA in June 2001. In December 2001, DEA claimed it was lost.
Subsequently a photocopy was resubmitted but UMASS/MAPS were told
in February 2002 that the photocopied application was invalid since
it didn't have an original signature. In July 2002, the original
application was returned, unprocessed, with a DEA date stamp showing
it had been received in June 2001. Dr. Craker resubmitted the original
application to DEA on August 20, 2002, which DEA finally acknowledged
receiving.
UMASS/MAPS worked with the Marijuana Policy Project on a Congressional
sign-on letter to the DEA expressing support for the UMass Amherst
license. The letter was submitted to DEA Administrator Asa Hutchinson
on June 6, 2002 (attached).
DEA Administrator Asa Hutchinson responded in a letter to Rep.
Barney Frank on July 1, 2002 (attached). DEA questioned whether
this new facility would be in the public interest, since NIDA currently
grows marijuana for research. In response, MAPS drafted a document
explaining why it would be in the public interest for DEA to grant
a license for the UMass Amherst facility, and submitted the document
to DEA, the Office of National Drug Control Policy (ONDCP) and NIDA.
The DEA has also indicated that granting such a license might conflict
with US international treaty obligations, specifically the Single
Convention on Narcotic Drugs. In response, UMASS/MAPS worked with
Graham Boyd of the ACLU Drug Policy Litigation Project and Peter
Barton Hutt and Alexei Silverman, of the DC law firm Covington &
Burling, on the development of a legal document detailing why US
international treaty obligations do not prevent the licensing of
the UMass Amherst facility.
On July 24, 2003, DEA finally filed a notice in the Federal Register
about Prof. Craker's application, with a public comment period ending
on September 23, 2003. On October 23, 2003, Senators Kennedy and
Kerry wrote a letter to the Administrator of the DEA expressing
their strong support for DEA licensing of the facility. UMASS/MAPS
expected DEA’s approval or rejection of Dr. Craker's application
sometime before the end of 2003 but that did not occur as DEA delayed
any decision as long as possible.
On July 21, 2004, MAPS, Prof. Craker and Valerie Corral filed lawsuits
against DEA and also against HHS/NIH/NIDA for obstructing medical
marijuana research. On July 29, 2004, MAPS filed a motion to consolidate
the lawsuit against the DEA and the lawsuit against HHS, NIH and
NIDA. Shortly thereafter, on November 22, 2004, the Court required
DEA to respond by December 22, 2004 to the portion of the lawsuit
against DEA about the UMass Amherst marijuana production facility.
On December 3, 2004, MAPS mailed petitions for reconsideration
to the DC Circuit Court of Appeals, asking again for the Court to
pressure HHS and DEA for not responding in 17 ½ months to
their applications to purchase 10 grams and import 10 grams, respectively,
in both cases for marijuana vaporizer research.
On December 10, 2004, DEA finally rejected the application from
Dr. Lyle Craker, UMass Amherst, seeking a license to establish a
MAPS-sponsored facility to produce marijuana for federally-approved
research, 3 and 1/2 years after the application was initially filed.
On February 28, 2005, DEA filed its pre-hearing statement in the
DEA Administrative Law Judge (ALJ) hearing. In DEA's initial "Order
to Show Cause" explaining its rationale for rejecting Prof.
Craker's application, DEA claimed that it would be against the public
interest for it to approve the license, and that, in any case, US
international treaty obligations prevented DEA from issuing the
license.
On April 22, 2005, UMass (Prof. Lyle Craker) filed his pre-hearing
statement to the DEA Administrative Law Judge for the hearing with
assistance from lead lawyer Julie Carpenter of Jenner & Block,
Allen Hopper of the ACLU Drug Law Reform Project, and Emanuel Jacobowitz,
Steptoe & Johnson, all working on a pro-bono basis.
On August 15, 2005, Chemic Laboratories received an official letter
indicating that NIDA refused to sell it10 grams of marijuana for
MAPS-sponsored research into the use of marijuana vaporizers. Chemic
Labs had applied to purchase the 10 grams more than two years before.
The initial round of hearings took place August 22-26, 2005, with
an additional week December 12-16, 2005, for DEA to present its
witnesses
During the August hearings, DEA seemingly abandoned the claim that
US international treaty obligations prevent it from licensing Prof.
Craker’s facility, with a DEA official testifying on the stand
that there is nothing in DEA law or policy that prevents it from
licensing individual researchers from growing different strains
of marijuana. The central issue remaining is whether it is in the
public interest for DEA to license the UMass Amherst facility or
whether NIDA should retain its monopoly on supply, a monopoly that
clearly obstructs research.
|
|
Statement Of Frederic M. Scherer
in re Professor Lyle Craker
Drug Enforcement Administration Docket No. 05-16
September 15, 2005
1. I have been asked by representatives of Professor Craker to
submit this analysis in connection with the Docket 05-16 proceedings
before the Drug Enforcement Administration (DEA). I do so pro bono
publico. I am professor emeritus at the John F. Kennedy School of
Government, Harvard University, and visiting professor at Haverford
College, teaching a course on the economics of industry. Copies
of my short-form biography and a list of my testimony in judicial
and regulatory proceedings are attached as Appendices A and B.
2. The issue, as I understand it, is fourfold. First, DEA has the
legal authority to designate production sources for the lawful production
of such controlled substances as marijuana and is mandated under
by 21 U.S.C. 823(a)(1) to "limit the importation and bulk manufacture
of such controlled substances to a number of establishments which
can produce an adequate and uninterrupted supply of these substances
under adequately competitive conditions for legitimate medical,
scientific, research, and industrial purposes." Second, I understand
that DEA has licensed a single source, Professor El Sohly at the
University of Mississippi, to produce marijuana under contract to
the National Institute on Drug Abuse (NIDA), the output of which
is allocated by NIDA. Third, DEA has recently licensed Professor
El Sohly to grow marijuana for lawful commercial purposes under
contract to private industry. Fourth, I understand that Dr. Craker
is seeking authorization to establish an alternative competitive
source at the University of Massachusetts, whose output is to be
used solely for lawful experimental purposes. That application has
been denied, but is under review by the DEA in this proceeding.
3. I have been asked to address the testimony on August 25, 2005,
of Mr. Matt Strait of DEA. Mr. Strait testified in effect that a
problem of deficient competition does not exist because the DEA-licensed
University of Mississippi source "provides marijuana to researchers
at a not for profit basis.... I just don't necessarily see the argument
for competition." In other words, because supplies are provided
at cost, there is no lack of competition, since, according to Mr.
Strait, the words used in the Code of Federal Regulations "all
seem to be geared around the economics."
4. My interpretation of this rather imprecise testimony is that,
since the University of Mississippi source prices its supplies of
marijuana at cost rather than above cost, there is no monopoly problem;
the requisites of competition are satisfied.
5. My understanding is that, in addition to providing only marijuana
of relatively low potency, NIDA has in the past denied applications
for marijuana supplies to be used solely for legitimate research.
For those applications, the supply is constrained to zero. When
there is a market demand for a commodity and there is no supply,
any reputable economist would agree that the true price is the so-called
shadow price, also called the implicit price, that is, the price
consistent with finite demand but zero supply. Under the circumstances
here, the shadow price is infinity for certain demand functions,
i.e., those derived from Cobb-Douglas utility functions (Paul Douglas
was a U.S. senator in the 1950s), or in other special cases, the
price just above the price at which the demander's demand is choked
off to a quantity of zero. In either case, such a shadow price is
higher, usually much higher, than the price at which a monopoly
would maximize its profits. And the monopoly price is higher than
a competitive price. Thus, when a monopoly supplier denies supplies
to legitimate demanders, there is a very significant impairment
of competition -- more significant than if the supplier merely levied
a monopoly price.
6. Scholars of all ideological shades who accept the basic premises
favoring a market economy agree that refusal to supply by an entity
with monopoly power is at least as undesirable as supplying at a
monopoly price. As Friedrich A. Hayek observed in his book, The
Road to Serfdom (1976 University of Chicago revised edition, p.
93):
Our freedom of choice in a competitive society rests on the fact
that, if one person refuses to satisfy our wishes, we can turn to
another. But if we face a monopolist we are at his mercy. And an
authority directing the whole economic system would be the most
powerful monopolist conceivable. While we need probably not be afraid
that such an authority would exploit this power in the manner in
which a private monopolist would do so, while its purpose would
presumably not be the extortion of maximum financial gain, it would
have complete power to decide what we are to be given and on what
terms... The power conferred by the control of production and prices
is almost unlimited.
Professor Hayek's book is considered the bedrock of contemporary
conservative economics. And I hardly need to say that Hayek abhorred
the kind of power he was describing. On the more liberal side (by
a modern, not 19th Century, definition of the term), consider the
1959 treatise by Carl Kaysen and Donald F. Turner, Antitrust Policy:
An Economic and Legal Analysis, p. 14:
The demand for limiting business power springs more often from those
who feel themselves at a disadvantage in interbusiness transactions
than it does from households ... Competition in this context is
desirable because it substitutes an impersonal market control for
the personal control of powerful business executives, or for the
personal control of government bureaucrats. The impersonality of
market regulation makes it fair in the eyes of those subject to
it; the sense of fairness is greater when the same restriction on
conduct is imposed by the market than when it is viewed as the result
of a personal decision by a powerful individual.
Shortly after publishing the book, Kaysen became an economic adviser
to President Kennedy; Turner was Assistant Attorney General for
Antitrust during the Johnson Administration.
7. In declaring under 21 U.S.C. 823(a) that controlled substances
should be supplied under "adequate competitive conditions"
for lawful purposes, the U.S. Congress was following a four-century
legal tradition. The seminal case is Darcy v. Allein, 1603, which
is reprinted in my compendium, Monopoly and Competition Policy,
vol. I, pp. 6-11. It condemned as contrary to the common law a grant
by Queen Elizabeth I of a monopoly over the supply of playing cards
in England. That and other High Court decisions led the Parliament
in 1623 to pass the Statute of Monopolies, which singled out patents
and copyrights as the sole allowable monopoly grants government
could make under English law. That policy was implicitly endorsed
by the U.S. Founding Fathers when they authorized Congress in Article
I, Section 8, of the Constitution to grant for limited times the
exclusive right to authors and inventors in their writings and discoveries,
but articulated expressly no other situations in which the government
was to confer exclusive rights.
8. It is my understanding that no exclusive patent rights limit
the supply of marijuana to lawful scientific users. Even for the
principal type of monopoly grant sanctioned in the U.S. Constitution,
Congress declared an explicit exemption in the Hatch-Waxman Drug
Price Competition and Patent Term Restoration Act of 1984 (Public
Law 98-417). The so-called Bolar amendment exempts would-be generic
suppliers of a drug from the exclusive rights of drug product patent
holders for the purpose of carrying out clinical trials in advance
of patent expiration so that their generic products can be ready
for marketing at the time valid patents expire.
9. A considerable part of my professional career has been devoted
to studying the relationships between market structure and technological
progress. One of my most important findings has been that innovation,
quality, and diversity of product characteristics satisfying consumers'
demands are more likely to be achieved when there are multiple producers
than when there is only one, i.e., a monopoly. For a summary, see
F. M. Scherer and David Ross, Industrial Market Structure and Economic
Performance (3rd edition: 1990), pp. 600-607 and 639-660.
10. To conclude, I believe Mr. Strait is quite wrong in testifying
that there is no impairment of competition when legitimate supplies
of marijuana are sold at cost to authorized customers. Competitive
problems emerge when costs are higher than those of alternative
sources, or when supplies are denied -- i.e., the quantity supplied
is zero -- to other would-be buyers who meet the scientific and/or
medical criteria of the Food and Drug Administration (FDA) or, in
the case of laboratory research, have the necessary DEA licenses.
Denial of a license to the University of Massachusetts to produce
marijuana for lawful scientific and medical purposes is contrary
to both the spirit of 21 U.S.C. 823(a)(1) and to sound public policy.
11. I swear that the statements in para. 1-10 above are true to
the best of my knowledge.
_____________________________
Frederic M. Scherer
|
|
Marijuana Pipe Dreams
John Tierney
August 27, 2005
New York times
When the Supreme Court ruled in June that states could not legalize
marijuana for medical uses, Justice Stephen Breyer voted with the
majority. But during oral arguments, he suggested an alternative
way for patients to get it: let the federal Food and Drug Administration
decide if marijuana should be a prescription drug.
"Medicine by regulation is better than medicine by referendum,"
he said. In theory, that sounds reasonable. But what if the officials
doing the regulation are afflicted with a bad case of Reefer Madness?
If you doubt this possibility, you should have been at a hearing
that began this week at the Drug Enforcement Administration's headquarters.
Lyle Craker, a professor of plant and soil sciences at the University
of Massachusetts, asked an administrative judge to overrule the
agency so he could grow marijuana for F.D.A.-approved research projects
by other scientists.
Dr. Craker is a well-regarded agronomist who's being supported
by the American Civil Liberties Union and both of his senators,
Edward Kennedy and John Kerry. But for four years he's been stymied
by the D.E.A., which first stalled and then finally denied his request
for a permit.
There are precedents for his re quest, because researchers already
get supplies of other drugs - like heroin, LSD and Ecstasy - from
independent laboratories licensed to make them. But researchers
who want marijuana have only one legal source: a crop grown in Mississippi
and dispensed by the National Institute on Drug Abuse.
Scientists say they need an alternative partly because the government's
marijuana is of such poor quality - too many seeds and stems - and
partly because the federal officials are so loath to give it out
for research into its medical benefits.
Discovering benefits, after all, would undermine the great anti-marijuana
campaign that has taken hold in Washington. Marijuana is deemed
to be such a powerful "gateway" to other drugs that it's become
the top priority in the federal drug war, much to the puzzlement
of many scientists, not to mention the police officers who see a
lot of worse drugs on the streets.
People with glaucoma and AIDS have sworn by the efficacy of marijuana,
and there have been studies by state health departments showing
that smoking marijuana is especially good at controlling nausea.
Scientists would like to test these effects, but they can't do good
studies until they get good marijuana.
Critics of medical marijuana say that it's unnecessary because
patients can obtain the benefits of its active ingredient, THC,
through a drug that's already available, Marinol. But many patients
say it doesn't work as well. They point to the case of the writer
Peter McWilliams, who said smoking marijuana was the only way to
control the nausea brought on by the mix of drugs he took for AIDS
and cancer.
He was forced to switch to Marinol after a D.E.A. investigation
led to his conviction for violating federal laws against marijuana.
In 2000, several weeks before he was to be sentenced, he was found
dead in his bathroom. He had choked on his own vomit.
Phillip Alden, a writer living in Redwood City, Calif., told me
that marijuana was a godsend for him in dealing with the effects
of AIDS. He said it eased excruciating pains in his fingertips,
controlled nausea and enabled him to avoid the wasting syndrome
that afflicts AIDS patients who are unable to eat enough food.
But Mr. Alden said only some kinds of marijuana worked - not the
weak variety provided by the federal government, which he smoked
during a research study.
"It was awful stuff," he said. "They started out with a very low-grade
plant, rolled it up with stems and seeds, and then freeze-dried
it so that they probably ruined any of the THC crystals. All it
did was give me headaches and bronchitis. The bronchitis got so
bad I had to drop out of the study."
Mr. Alden was scheduled to testify at this week's hearing, but
he told me he had to withdraw because the D.E.A. refused to give
him legal immunity if he admitted using marijuana not from the government.
It's a shame the judge will be making a decision without hearing
him, but I can understand Mr. Alden's hesitancy.
D.E.A. officials have already shown they're quite capable of persecuting
someone who uses marijuana to deal with AIDS, and they may well
be even more eager to go after someone who encourages research into
their least favorite drug. When it comes to marijuana research,
the federal policy is "Just Say Know-Nothing." |
|
- Transcript of
court hearing, Monday, August 22, 2005
Craker opening statement by Julie Carpenter, Witnesses are Lyle
E. Craker and Irwin G. Martin
- Transcript of
court hearing, Tuesday, August 23, 2005
Witnesses are Lyle E. Craker, Barbara Roberts, John Vasconcellos,
Dale Gieringer
- Transcript of
court hearing, Wednesday, August 24, 2005
Witness is Rick Doblin
- Transcript of
court hearing, Thursday, August 25, 2005
DEA opening statement by Brian Bayly, Witness is Matthew Strait
- Transcript of
court hearing, Friday, August 26, 2005
Witness is Matthew Strait |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|